2014
DOI: 10.1021/ol500971c
|View full text |Cite
|
Sign up to set email alerts
|

Enantioselective Synthesis of an HCV NS5a Antagonist

Abstract: A concise, enantioselective synthesis of the HCV NS5a inhibitor MK-8742 (1) is reported. The features of the synthesis include a highly enantioselective transfer hydrogenation of an NH imine and a dynamic diastereoselective transformation. The synthesis of this complex target requires simple starting materials and nine linear steps for completion.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
46
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 69 publications
(46 citation statements)
references
References 39 publications
0
46
0
Order By: Relevance
“…Ak ey intermediate in the synthesis of elbasvir, [23] which has been approved for the treatment of hepatitis Cv irus (HCV) infection, the monohydroxylated product 43 was formed in 71 %yield with little loss of enantiomeric purity.I nt he case of the challenging N-heterocyclic substrate 44, [24] the desired phenol 45 was also formed in good yield. Ak ey intermediate in the synthesis of elbasvir, [23] which has been approved for the treatment of hepatitis Cv irus (HCV) infection, the monohydroxylated product 43 was formed in 71 %yield with little loss of enantiomeric purity.I nt he case of the challenging N-heterocyclic substrate 44, [24] the desired phenol 45 was also formed in good yield.…”
mentioning
confidence: 99%
“…Ak ey intermediate in the synthesis of elbasvir, [23] which has been approved for the treatment of hepatitis Cv irus (HCV) infection, the monohydroxylated product 43 was formed in 71 %yield with little loss of enantiomeric purity.I nt he case of the challenging N-heterocyclic substrate 44, [24] the desired phenol 45 was also formed in good yield. Ak ey intermediate in the synthesis of elbasvir, [23] which has been approved for the treatment of hepatitis Cv irus (HCV) infection, the monohydroxylated product 43 was formed in 71 %yield with little loss of enantiomeric purity.I nt he case of the challenging N-heterocyclic substrate 44, [24] the desired phenol 45 was also formed in good yield.…”
mentioning
confidence: 99%
“…The rat PK profiles of several selected analogs are summarized in Table 3. The halogenated derivatives (13,14,17,18, and 21) bearing either one or two halogens demonstrated comparable pharmacokinetic profiles to each other. It seems that the halogen substitution on the phenyl group had minimum effect on the rat PK profiles as well.…”
Section: Mk-8742mentioning
confidence: 92%
“…12 The key intermediate dibromide 3 can be prepared either by reaction of dibromide 2 and indole 1 10,11 or from aldehyde 4 and indoline 5. 13 Compound 3 was then converted to bis-pinacol boronate ester 6 which was then treated, under Suzuki coupling conditions, with imidazole bromide 7 11 to afford the bisBoc intermediate. Treatment of the bis-Boc intermediate, under acid conditions, followed by HATUmediated amide coupling with methoxycarbonyl-L-valine generated a mixture of two diastereomers at the aminal carbon.…”
mentioning
confidence: 99%
“…93 Imine hydrogenation catalyzed by iridium or rhodium to give a primary amine was evaluated during the enantioselective synthesis of a hepatitis C NS5A antagonist, but due to challenges with imine hydrolysis, transfer hydrogenation using tethered Ru catalysts proven superior. 94 Phosphine-free asymmetric imine reductions have also been reported. Frustrated Lewis pairs have been shown to catalyze hydrogenation of the imines 32, 95 with an example shown in eq 37.…”
Section: Carbon-nitrogen Bond Reductionsmentioning
confidence: 98%